The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

mybiosense.com

Founded Year

2018

Stage

Seed VC | Alive

Total Raised

$3.78M

Last Raised

$2.2M | 2 yrs ago

About Biosense

Readout Health provides metabolic insights to consumers and patients. The Company developed Biosense, a medical-grade, non-invasive breath ketone device and mobile app. Biosense is available DTC and utilized in the clinical setting where fat burn and nutritional ketosis therapy is used to treat chronic diseases. The Biosense device integrates with a number of consumer and integrated health mobile apps like Cronometer and supports a number of clinical trials.

Biosense Headquarters Location

2940 Locust Street

Saint Louis, Missouri, 63103,

United States

314-369-7477

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Biosense

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biosense is included in 5 Expert Collections, including Conference Exhibitors.

C

Conference Exhibitors

5,302 items

D

Diabetes

1,750 items

D

Digital Health

13,099 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health Monitoring & Diagnostics

701 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

B

Biopharma Tech

260 items

Biosense Patents

Biosense has filed 3 patents.

The 3 most popular patent topics include:

  • Acoustics
  • Analytical chemistry
  • Respiratory therapy
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/30/2020

8/2/2022

Analytical chemistry, Acoustics, Respiratory therapy, Spectroscopy, Molecular biology

Grant

Application Date

4/30/2020

Grant Date

8/2/2022

Title

Related Topics

Analytical chemistry, Acoustics, Respiratory therapy, Spectroscopy, Molecular biology

Status

Grant

Latest Biosense News

09:00 EDT Readout Health Biosense device to be tested in JDRF-funded clinical trial in people with Type 1 Diabetes using SGLT in...

Jul 12, 2022

News provided by Share this article Share this article $360,000 grant to review safety and accuracy of Biosense® device aimed at DKA risk mitigation in patients using SGLTi drug class. ST. LOUIS, July 12, 2022 /PRNewswire/ -- Readout Health, a medical digital health startup, announces a sponsored research agreement with Washington University School of Medicine in St. Louis that received a $360,000 research grant from JDRF. The two-year grant is aimed at testing the efficacy of the Biosense® handheld breath ketone monitor in persons with type 1 diabetes (T1D) during usual care with insulin and with the addition of a sodium glucose transporter inhibitor (SGLT2i) drug. Janet McGill, MD, a professor at Washington University School of Medicine and the recipient of the American Diabetes Association's 2022 Outstanding Physician Clinician award, will serve as the principal investigator. Biosense® device and health app Biosense® was launched in 2020 as the non-invasive option to capillary blood testing or urine testing for in-home biofeedback of fat oxidation levels based on nutrition and exercise. While metabolic disorders like type 2 diabetes (T2D) and obesity have protocols often seeking higher ketone levels, T1D patients can be at a considerable risk with elevated ketones, a problem potentially compounded by medications like SGLT2i if left unchecked. According to Dr. McGill, "Routine monitoring of ketones may alert patients to impeding ketosis and help to prevent episodes of ketoacidosis. Ketone monitoring should be easy, non-invasive, low-cost, and accessible for repeated use to be effective." Biosense®, a class 1 designated breath ketone analyzer, will be tested for its ability to detect ketosis in persons with T1D during usual care and during usual care plus SGLTi therapy. Ultimately, the goal is to reduce the risk of diabetic ketoacidosis (DKA), which is increased when persons with T1D take an SGLT2i. This increased risk of life-threatening DKA has caused the FDA to withhold approval of SGLT2i in persons with T1D, despite proven benefits of drugs in this class for reduction in the risks of elevated glucose levels, progressive chronic kidney disease and hospitalizations for heart failure in persons with and without type 2 diabetes. According to Jonathan Rosen, PhD, JDRF Associate Director of Research, "SGLT inhibitors are improving outcomes in glucose control, heart disease, and kidney disease in non-type 1 diabetes populations, but are rarely used in type 1 diabetes because they increase the risk of DKA. Development of ketone monitoring technologies like Biosense are a critical part of the strategy to enable safe, effective use of SGLT inhibitors in type 1 diabetes." The JDRF funded research grant is awarded directly to Washington University School of Medicine at St. Louis with first patients targeted late summer. About Readout Health Readout Health is developing digital breath biomarker technologies for chronic disease prevention, management, and reversal. Readout's patented breath sampling technology isolates high concentration samples of breath compounds within handheld medical devices an supportive mobile apps. Targeting behavior modification through precision biofeedback, Biosense®, a Class 1 medical device, was launched as an FDA Class 1 medical device after a successful 2019 clinical trial , enabling pharma and academic researchers and clinicians to monitor patient dosing of therapeutic ketosis (area-under-the-curve) in several therapeutic areas, including metabolic, neurocognitive, and oncology. For more information, visit  https://mybiosense.com . About JDRF JDRF's mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit https://www.jdrf.org . Media Contact: Press Team (314)-369-7477 [email protected] SOURCE Readout Health

Biosense Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Biosense Rank

  • When was Biosense founded?

    Biosense was founded in 2018.

  • Where is Biosense's headquarters?

    Biosense's headquarters is located at 2940 Locust Street, Saint Louis.

  • What is Biosense's latest funding round?

    Biosense's latest funding round is Seed VC.

  • How much did Biosense raise?

    Biosense raised a total of $3.78M.

  • Who are the investors of Biosense?

    Investors of Biosense include iSelect Fund and BioGenerator.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.